This study was aimed to evaluate the long-term effects of telbivudine（Ld T） in the treatment of chronic hepatitis B（CHB） and HBV-related liver cirrhosis（LC） and to observe the changes of immunological responses ...This study was aimed to evaluate the long-term effects of telbivudine（Ld T） in the treatment of chronic hepatitis B（CHB） and HBV-related liver cirrhosis（LC） and to observe the changes of immunological responses during Ld T treatment. Clinical data of 80 CHB and 28 HBV-related LC patients who were administered with Ld T for 108 weeks and followed up were retrospectively analyzed. The liver function indicators including ALT, AST and γ-GT, HBV DNA copy number in serum and the rates of hepatitis B e antigen（HBe Ag） seroconversion were analyzed before and 12, 24, 36, 48, 60, 72, 84, 96 and 108 weeks after Ld T treatment in CHB and LC groups. Four serum fibrosis-related markers, including hyaluronic acid（HA）, human laminin（LN）, human type Ⅳ collagen（Ⅳ-C） and human N-terminal procollagen Ⅲ peptide（PC-Ⅲ）, were detected before and after Ld T treatment in LC group. The results showed favorable viral suppression and biochemical responses after treatment with Ld T for 12 weeks, and a high rate of virological and biochemical control was maintained during the course of 108-week treatment in both CHB and LC groups. The four fibrosis-related markers, especially HA and LN, were down-regulated to some degrees in LC group. Moreover, Ld T treatment led to the fluctuation of the circulating interferon-γ（IFN-γ） and interleukin-10（IL-10） levels at different time points in CHB group. It was concluded that Ld T could favorably lead to the virological suppression and biochemical remission. Besides, IFN-γ and IL-10 may represent a suitable and effective predictor of responsiveness during Ld T therapy.展开更多
文摘This study was aimed to evaluate the long-term effects of telbivudine（Ld T） in the treatment of chronic hepatitis B（CHB） and HBV-related liver cirrhosis（LC） and to observe the changes of immunological responses during Ld T treatment. Clinical data of 80 CHB and 28 HBV-related LC patients who were administered with Ld T for 108 weeks and followed up were retrospectively analyzed. The liver function indicators including ALT, AST and γ-GT, HBV DNA copy number in serum and the rates of hepatitis B e antigen（HBe Ag） seroconversion were analyzed before and 12, 24, 36, 48, 60, 72, 84, 96 and 108 weeks after Ld T treatment in CHB and LC groups. Four serum fibrosis-related markers, including hyaluronic acid（HA）, human laminin（LN）, human type Ⅳ collagen（Ⅳ-C） and human N-terminal procollagen Ⅲ peptide（PC-Ⅲ）, were detected before and after Ld T treatment in LC group. The results showed favorable viral suppression and biochemical responses after treatment with Ld T for 12 weeks, and a high rate of virological and biochemical control was maintained during the course of 108-week treatment in both CHB and LC groups. The four fibrosis-related markers, especially HA and LN, were down-regulated to some degrees in LC group. Moreover, Ld T treatment led to the fluctuation of the circulating interferon-γ（IFN-γ） and interleukin-10（IL-10） levels at different time points in CHB group. It was concluded that Ld T could favorably lead to the virological suppression and biochemical remission. Besides, IFN-γ and IL-10 may represent a suitable and effective predictor of responsiveness during Ld T therapy.
